### **Guidelines for the Blood Transfusion Services**

### **Updates**

http://www.transfusionguidelines.org/red-book/latest-updates

# Updates to the Red Book

### April 2024

#### Change Notification No. 05 - 2024

- · Chapter 21 Tissue banking: tissue retrieval and processing
- Chapter 7 Requirements for the timing of testing for Hematopoietic Progenitor Cells (HPCs)

#### March 2024

#### Change Notification No. 03 - 2024

- Chapter 2 Quality in blood and tissue establishments and hospital blood banks
- Chapter 6 Evaluation and manufacture of blood components
- Chapter 7 Specifications for blood components
- Annexe 3 Provisional Components
- Annexe 4 Redundant Components
- Annexe 5 Blood Components for Contingency Use

### December 2023

#### Change Notification No. 40 - 2023

- Chapter 7.31 Irradiated components
- Chapter 9.2 Microbiology screening
- Chapter 9.3 Specific screening targets
- Chapter 9.4 Reinstatement of blood donors
- Chapter 9.7 Recommended standards for environmental monitoring (EM) of processing facilities

# November 2023

## Change Notification No. 39 - 2023

• Annexe 7 - Requirements for the timing of testing for HPCs

# September 2023

#### Change Notification No. 16 - 2023

- Chapter 4 Premises and quality assurance at blood donor sessions
- Chapter 5 Collection of a blood or component donation
- Chapter 11 Reagent manufacture
- Chapter 12 Donation testing (red cell immunohaematology)
- Chapter 13 Patient testing (red cell immunohaematology)
- Chapter 14 Guidelines for the use of DNA/PCR techniques in Blood Establishments
- Chapter 15 Molecular typing for red cell antigens
- Chapter 16 HLA typing and HLA serology
- Chapter 17 Granulocyte immunology
- Chapter 18 Platelet immunology
- Chapter 22 Haemopoietic progenitor cells
- Annexe 7 Requirements for the timing of testing for HPCs

### April 2023

### Change Notification No. 22 - 2023

Annexe 3: Provisional Components - Annexe 3.5 - Red Cells and Plasma, Leucocyte Depleted

### February 2023

### Change Notification No. 06 - 2023

- Chapter 9 Microbiology tests for donors and donations: general specifications for laboratory test procedures
- Chapter 10 Investigation of suspected transfusion-transmitted infection
- Chapter 19 Tissue Banking: general principles
- Chapter 20 Tissue Banking: selection of donors
- Chapter 21 Tissue Banking: tissue retrieval and processing
- Annexe 6 Advanced Therapy Medicinal Products (ATMPs)

#### June 2022

#### Change Notification No. 33 - 2022

 Chapter 8 - Evaluation of novel blood components, production processes and blood packs: generic protocols

#### March 2022

#### Change Notification No. 09 - 2022

• Chapter 7 - Human Plasma for Fractionation Leucocyte Depleted

# February 2022

### Change Notification No. 10 - 2022

Annexe 4 - Redundant Components: Convalescent Plasma

## Change Notification No. 11 - 2022

Annexe 3 - Provisional Components: Whole blood, leucocyte depleted, for clinical studies

#### Change Notification No. 12 - 2022

 Annexe 3 - Provisional Components: Cryoprecipitate pooled, leucocyte depleted, extended shelf life post-thaw

### January 2022

#### Change Notification No. 44 - 2021

• Annexe 5 - Blood Components for Contingency Use

### June 2021

#### Change Notification No.18 - 2021

 Chapter 3 - Care and selection of whole blood and component donors (including donors of predeposit autologous blood)

#### January 2021

#### Change Notification No. 03 - 2021

• Chapter 21 - Tissue banking: tissue retrieval and processing

#### November 2020

#### Change Notification No. 66 - 2020

Annexe 3 - Provisional Component: Convalescent Plasma (COVID-19), FFP, Leucocyte Depleted

#### Change Notification No. 67 - 2020

 Annexe 3 - Provisional Component: Convalescent Plasma (COVID-19), FFP, for Neonates and Infants, Leucocyte Depleted

### October 2020

### Change Notification No. 35 - 2020

Annexe 3 - Provisional Component: Whole Blood, Leucocyte Depleted for Clinical Studies

### August 2020

### Change Notification No. 47 - 2020

Annexe 5 - Platelets, Apheresis, Leucocyte Depleted, at Reduced Dose as a Contingency

### June 2020

#### Change Notification No. 32 - 2020

Annexe 3 - Provisional Component: Red Cells and Plasma, Leucocyte Depleted

# May 2020

#### Change Notification No. 23 - 2020

• Chapter 7 - Fresh Frozen Plasma for Neonates and Infants, Leucocyte Depleted

### Change Notification No. 24 - 2020

• Chapter 7 - Cryoprecipitate for Neonates and Infants, Leucocyte Depleted

### Change Notification No. 25 - 2020

• Chapter 7 - Fresh Frozen Plasma, Leucocyte Depleted

#### Change Notification No. 27 - 2020

• Chapter 3 - Blood Tests

# April 2020

#### Change Notification No. 19 - 2020

• Annexe 4 - Redundant Components

#### Change Notification No. 20 - 2020

Annexe 4 - Granulocytes, Apheresis

#### Change Notification No. 21 - 2020

Annexe 5 - Blood Components for Contingency Use

#### Change Notification No. 22 - 2020

Annexe 5.1 - Red Cells in Additive Solution, Leucocyte Depleted, Extended Shelf Life

### November 2019

### Change Notification No. 34 - 2019

• Chapter 7 - Platelets in Plasma and Additive Solution for Neonatal Use, Leucocyte Depleted

# April 2017

# Change Notification No. 10 - 2017

Chapter 7 - Use of plasma from first time donors

# January 2017

### Change Notification No. 01 - 2017

• Chapter 11 - General guidelines for reagent red cell manufacture

#### Change Notification No. 02 - 2017

Chapter 17 and Chapter 18 - Additional guidance re HNA and HPA antibody detection methods

### August 2016

#### Change Notification No. 32 - 2016

Chapter 7 - Red Cells, Thawed and Washed, Leucocyte Depleted

#### Change Notification No. 33 - 2016

Chapter 7 - Removal of red cells from a controlled temperature environment

#### Change Notification No. 34 - 2016

Chapter 7 - Removal of upper limit of pH from Platelet Components

### June 2016

### Change Notification No. 31 - 2016

• Annexe 3 - Trial Components

## May 2016

# Change Notification No. 23 - 2016

Chapter 21 - Tissue banking: Tissue retrieval and processing

### **April 2016**

### Change Notification No. 16 - 2016

• Chapter 7 - Fresh Frozen Plasma, Leucocyte Depleted

### January 2016

#### Change Notification No. 12 - 2016

 Chapter 9 - Microbiology tests for donors and donations: general specifications for laboratory test procedures

#### December 2015

#### Change Notification No. 18 - 2015

 Chapter 7 - Interruptions to agitation and testing of Platelets, Pooled, Buffy Coat Derived, Leucocyte Depleted and Platelets, Apheresis, Leucocyte Depleted

### Change Notification No. 19 - 2015

Chapter 7 - Platelets in Additive Solution and Plasma, Leucocyte Depleted

#### Change Notification No. 20 - 2015

Chapter 6 - Specific gravity of blood components

#### Change Notification No. 21 - 2015

Chapter 7 - Leucocyte depletion of blood components - Concessionary release

#### Change Notification No. 22 - 2015

Chapter 7 - Concessionary Release Limits for Selected Components

### Change Notification No. 23 - 2015

• Chapter 9 - Removal of Chapter 9.4.2. and Figure 9.6 in Chapter 9

### Change Notification No. 29 - 2015

Chapter 25.6 - Table 25.5: Protocol 000001 – blood component dispatch information

#### Change Notification No. 30 - 2015

Chapter 7 - Red Cells, Washed, Leucocyte Depleted

### January 2015

#### Change Notification No. 01 - 2015

• Chapter 25.6 - Tables 25.4 and 25.5: Protocol 000001 - blood component dispatch information

#### June 2014

### Change Notification No. 25 - 2014

• Chapter 5 - Appendix I: Points of care

### January 2014

### Change Notification No. 15 - 2013

Chapter 3 - Appendix I: Extra-corporeal volume tables

### Change Notification No. 16 - 2013

Errata - Amended pages

- Chapter 7.9.1 Platelets, Pooled, Buffy Coat Derived, Leucocyte Depleted
- Chapter 7.11.1 Platelets in Additive Solution and Plasma, Leucocyte Depleted
- Chapter 9.5.3.1 Single-test system
- Chapter 12.11.2 Blood and blood components from group O donors with high titres of anti-A, anti-B and/or anti-A,B
- Chapter 7.12.1 Platelets in Additive Solution, Leucocyte Depleted

#### Change Notification No. 17 - 2013

Shelf-life (when frozen) of FFP, cryoprecipitate, cryodepleted plasma and MB-treated FFP

- Chapter 7.15 Fresh Frozen Plasma, Leucocyte Depleted
- Chapter 7.16 Fresh Frozen Plasma, Methylene Blue Treated and Removed, Leucocyte Depleted
- Chapter 7.17 Cryoprecipitate, Leucocyte Depleted
- Chapter 7.18 Cryoprecipitate Pooled, Leucocyte Depleted
- Chapter 7.20 Plasma, Cryoprecipitate Depleted, Leucocyte Depleted
- Chapter 7.27 Fresh Frozen Plasma, Neonatal Use, Methylene Blue Treated and Removed, Leucocyte Depleted
- Chapter 7.28 Cryoprecipitate, Methylene Blue Treated and Removed, Leucocyte Depleted
- Chapter 7.33 Cryoprecipitate, Pooled, Methylene Blue Treated and Removed, Leucocyte Depleted

### June 2013

### **Change Notification No. 11 - 2013**

Chapter 7.33 - Cryoprecipitate, Pooled, Methylene Blue Treated and Removed, Leucocyte Depleted

#### Change Notification No. 12 - 2013

• Annexe 3 - Platelets in Additive Solution and Plasma, Leucocyte Depleted, Pathogen-reduced